New hope for hard-to-treat lymphoma: targeted drug combo shows promise
NCT ID NCT04665765
First seen Oct 31, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This study tests a new combination of drugs (polatuzumab vedotin plus standard chemotherapy and immunotherapy) as the first treatment after lymphoma returns or doesn't respond. About 41 adults with diffuse large B-cell lymphoma will receive this therapy to see if it can shrink tumors and control the disease. The goal is to improve response rates while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.